• 关于我们
  • 律师
  • 执业领域
    • 行业
        • 技术、媒体和通信 (TMC)
        • 国际私人财富
        • 房地产、基础设施和能源
        • 生命科学和医疗保健
        • 航空航天与国防
        • 自动化
        • 商业和专业服务
        • 化学制品
        • 消费与零售
        • 金融机构和保险
        • 酒店与休闲
        • 物流与运输
        • 制造业与工业
        • 公共服务和教育
    • 法律服务
        • Artificial intelligence
        • 银行与金融
        • 品牌和广告
        • 商业和消费者合同
        • 竞争、欧盟与贸易
        • 版权和媒体
        • 公司犯罪与合规
        • 国际企业并购与资本市场
        • 数据和网络
        • 纠纷和调查
        • 就业、养老金和流动性
        • 环境规划与监管
        • 环境、社会和公司治理 (ESG)
        • 信息技术
        • Multi-service
        • 专利与创新
        • 私人客户
        • 私募股权
        • 项目、能源和基础设施
        • 房地产与建筑
        • Regulation
        • 重组和破产
        • 税务
        • 风险投资
  • 法域
    • 欧洲
        • 位置
        • 奥地利
        • 比利时
        • 捷克共和国
        • 法国
        • 德国
        • 匈牙利
        • Italy
        • 荷兰
        • 波兰
        • Portugal
        • 爱尔兰共和国
        • 斯洛伐克
        • Spain
        • 英国
        • 乌克兰
          团体
        • CEE Turkish Desk
        • 法国德国团队
        • 办公室
    • 中东和非洲
        • 位置
        • 中东
        • 阿联酋
          团体
        • 非洲团队
        • 以色列团队
        • 办公室
    • 美洲
        • 位置
        • Latin America
        • 美国
          团体
        • 巴西团队
        • 办公室
    • 亚洲
        • 位置
        • 亚洲
        • 中国
        • 韩国
          团体
        • 印度团队
        • 日本团队
        • 办公室
  • 新闻和观点
    • 观点
        • 热点话题
        • Artificial intelligence
        • Data Centre Expertise
        • The EU Whistleblower Directive
        • German Supply Chain Act
        • Unified Patent Court
          Content hub
        • Global Data Hub
        • Interface: 技术、知识产权和媒体法
        • Podcasts
        • Synapse
        • 浏览所有观点
    • 活动
        • 亲自
        • 在线的
        • Browse All Events
    • 新闻
        • 媒体中心
        • 工作亮点
        • 律所新闻
        • 查看全部
  • 职业发展
  • ZH
    • English
    • 中文(简体)
    • Français
    • Deutsch
  • Home
  • People
  • Colin McCall
Colin McCall
Colin McCall

Colin McCall

合伙人

  • 伦敦 英国
+44 20 7300 4661
vCard
发送电子邮件给我 Call me
奖励

Managing Intellectual Property – IP Stars 2024

Notable practitioner

Scroll to featured award

Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

专长

执业领域和服务团队

专利与创新
专利与专有技术商业协议的起草和谈判
专利与专有技术争议解决
生命科学监管咨询
印度团队

行业

酒店与休闲
房地产
医疗器械
生命科学和医疗保健类房地产

CV

Since 2020 Partner, Taylor Wessing
2016 - 2020 Senior Counsel, Taylor Wessing
2010 - 2016 Senior Associate, Taylor Wessing
2006 - 2010 Associate,Taylor Wessing
2004 - 2006 Associate, Linklaters
2002 - 2004 Trainee, Linklaters
2013 MSc Energy Environmental Technology and Economics, London City University
2005 Diploma in Intellectual Property Law and Practice, Bristol University
2004 Admitted as a lawyer, England, Wales
2000 Graduate Diploma in Law, Nottingham Law School
1998 BSc in Cell Biology, Durham University

职业发展

Since 2020 Partner, Taylor Wessing
2016 - 2020 Senior Counsel, Taylor Wessing
2010 - 2016 Senior Associate, Taylor Wessing
2006 - 2010 Associate,Taylor Wessing
2004 - 2006 Associate, Linklaters
2002 - 2004 Trainee, Linklaters

教育

2013 MSc Energy Environmental Technology and Economics, London City University
2005 Diploma in Intellectual Property Law and Practice, Bristol University
2004 Admitted as a lawyer, England, Wales
2000 Graduate Diploma in Law, Nottingham Law School
1998 BSc in Cell Biology, Durham University

语言

English

奖励

Managing Intellectual Property – IP Stars 2024

Featured

Notable practitioner

Legal 500 UK 2023

Life Sciences and Healthcare - "Stand out partner for me has been Colin McCall, who has single-handedly helped us get a hugely complex licensing deal over the line. His understanding of the detail of licence terms and the complex background to the development of the IP was instrumental to making all the parties make appropriate concessions to getting a deal over the line, and avoiding lengthy stand offs and threats of walking away."

Legal 500 UK 2022

Biotechnology: "Colin McCall has provided excellent service – he makes sure to understand the client’s needs and reliably delivers high-quality work within the agreed timelines and budgets. He is an excellent communicator, very personable and a pleasure to deal with."

Legal 500 UK 2022

Intellectual Property

IP - contentious and non-contentious

Experience

Healx raises $47 million in its Series C funding

Advised Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases based in Cambridge UK, on its $47 million Series C funding. The funding was co-led by Silicon Valley-based R42 Group and Atomico, one of Europe’s largest venture capital firms, with participation from new and existing investors including Balderton, Jonathan Milner, Global Brain, btov, Ayana Capital, o2h and VU Venture Partners.

Press release
Ross McNaughton
Oli Denne
Colin McCall

Advising gene therapy company AlveoGene on its complex spinout and launch investment

We have advised AlveoGene, a new UK gene therapy company on its complex spinout from the Gene Therapy Consortium of Imperial College and the Universities of Oxford and Edinburgh focusing on rare respiratory diseases, as well as on its seed round investment.

Press release
Colin McCall
Ross McNaughton
Bella Thornton-Clark

Ceres Power on numerous strategic collaborations

Including on its transformational licensing and equity investment deals done with Weichai Power in China and with Robert Bosch GmbH in respect of Ceres Power's solid oxide fuel cell technology.

Colin McCall

Glenmark Pharma on the sale of its portfolio of CNS products in Poland to Neuraxpharm

Advised Glenmark Pharma on its divestment of its CNS business in Poland including its portfolio of generics and branded generics products and the transfer of its commercial team in Poland to private equity backed Neuraxpharm, a specialty pharmaceutical company focused on the treatment of CNS disorders.

Press release
Colin McCall
Emma Danks
Simon Jupp
Jason Rawkins
Graham Samuel-Gibbon

Oxford BioMedica on its transformational deal with Novartis re: Kymriah

Oxford BioMedica on various commercial and licensing deals including its collaboration, development and licence agreement with Novartis in respect of Kymriah, which became the first gene therapy ever to receive FDA approval and on its manufacturing agreements for clinical and commercial supply of Kymriah to Novartis.

Colin McCall

Apotex's EUR74 million sale of subsidiaries to Aurobindo

Apotex on the sale of six European subsidiaries in Belgium, Poland, the Netherlands, Czech Republic and Spain, to Aurobindo for EUR74 million. This highly complex transaction involved the share transfer of subsidiaries in multiple jurisdictions being co-ordinated and managed by our UK team. We simultaneously advised on a multitude of business separation, ongoing product supply agreements and IP licences for the European business to continue operating after being removed from the Apotex group.

Colin McCall
Simon Cohen
Tasmina Goraya, PhD
Jason Rawkins
Simon Jupp
Bart Hunnekens
Roos Seesing

最新新闻和观点

View Colin's insights
点击此处了解更多
酒店与休闲

Advising SENISCA on its partnership with L'Oréal

2025年7月4日

作者 Colin McCall 以及 Charlie Adams

Glass.Mapper.Sc.Fields.Image?.Alt
酒店与休闲

Antiverse and Nxera Pharma enter collaboration to design novel GPCR-targeted antibody therapeutics

2024年11月7日

作者 Colin McCall 以及 Charlie Adams

点击此处了解更多
Glass.Mapper.Sc.Fields.Image?.Alt
酒店与休闲

Advising Cumulus Oncology on its exclusive GPR68 licence and development collaboration with leadXpro

2024年9月2日

作者

点击此处了解更多
View Colin's insights

Related news & insights

专利与创新

Preliminary injunctions in Poland

2025年11月5日
Briefing

作者 Bartosz Świdrak 以及 Karolina Ciąglewicz

点击此处了解更多
酒店与休闲

Biotechnology as a security issue: Why dual-use control and adaptive regulation are crucial for national sustainability

2025年11月3日
Quick read

作者 Dr. Niclas von Woedtke, MBA (Kellogg/ WHU)

点击此处了解更多
专利与创新

Preliminary injunctions in Belgium

2025年10月29日
Briefing

作者

点击此处了解更多
专利与创新

Preliminary injunctions in France

2025年10月22日
Briefing

作者

点击此处了解更多
酒店与休闲

Advertising skinny jabs – regulators react

2025年10月15日
Quick read

作者 Alison Dennis 以及 Alice Matthews

点击此处了解更多
专利与创新

Preliminary injunctions in Austria

2025年10月15日
Briefing

作者

点击此处了解更多
税收

Ireland's Budget 2026 – the commercial real estate measures announced

2025年10月13日
Quick read

作者 Órlaith Molloy 以及 Bríd Kenny

点击此处了解更多
酒店与休闲

Reform of the Veterinary Medicines Act

2025年10月13日
Briefing

作者 Dr. Daniel Tietjen 以及 Daniel Dietrich

点击此处了解更多
专利与创新

Preliminary injunctions in Ireland

2025年10月8日
Briefing

作者 Hannah Garvey 以及 Eoin Martyn

点击此处了解更多
专利与创新

Once daily, twice defeated in Ireland

2025年10月6日
Quick read

作者 Hannah Garvey 以及 Eoin Martyn

点击此处了解更多
View all insights

相关人员

英国
Global

Tom Foster

合伙人

伦敦
+44 20 7300 4954
发送电子邮件给我
查看个人资料

Michael Washbrook

合伙人

伦敦
+44 20 7300 4274
发送电子邮件给我
查看个人资料
Chris Thornham

Chris Thornham

合伙人

伦敦
+44 20 7300 4817
发送电子邮件给我
查看个人资料

Kim Wedral

合伙人

剑桥
+44 1223 446 400
发送电子邮件给我
查看个人资料
Charlie Adams

Charlie Adams

高级法律顾问

剑桥
+44 1223 446 400
发送电子邮件给我
查看个人资料
Adrian Toutoungi

Adrian Toutoungi

合伙人

剑桥
+44 1223 446 420
发送电子邮件给我
查看个人资料

Alice Matthews

律师

伦敦
+44 20 7300 7000
发送电子邮件给我
查看个人资料

Nicholas Vollers

律师

伦敦
+44 20 7300 7000
发送电子邮件给我
查看个人资料
Amanda Ebbutt

Amanda Ebbutt

合伙人

伦敦
+44 20 7300 7130
发送电子邮件给我
查看个人资料
Matthew Royle

Matthew Royle, Ph.D.

合伙人

伦敦
+44 20 7300 4608
发送电子邮件给我
查看个人资料
Full team
Marie Keup

Marie Keup

合伙人

布鲁塞尔
+32 2 3202 252
发送电子邮件给我
查看个人资料
Margot van Gerwen

Margot van Gerwen

法律顾问

埃因霍温
+31 88 02 43 112
发送电子邮件给我
查看个人资料
Antoine Hendrix

Antoine Hendrix

律师

布鲁塞尔
+32 2 3202 265
发送电子邮件给我
查看个人资料

Julie Chiu

高级法律顾问

伦敦
+44 20 7300 7000
发送电子邮件给我
查看个人资料
Sophie van Asten

Sophie van Asten

法律顾问

阿姆斯特丹
+31 88 02 43 075
发送电子邮件给我
查看个人资料
Nigel Stoate

Nigel Stoate

合伙人

伦敦
+44 20 7300 4783
发送电子邮件给我
查看个人资料

Marco Berlage

高级律师

杜塞尔多夫
+49 211 8387 0
发送电子邮件给我
查看个人资料
Chris Thornham

Chris Thornham

合伙人

伦敦
+44 20 7300 4817
发送电子邮件给我
查看个人资料

Christoph de Coster, LL.M. (UC Davis)

特邀律师

慕尼黑
硅谷
+49 89 21038 0
发送电子邮件给我
查看个人资料
Geert Theuws

Geert Theuws

法律顾问

埃因霍温
+31 88 02 43 197
发送电子邮件给我
查看个人资料
Full team

与我会面:

查看所有活动
订阅
  • 关于我们
  • Campaigns and online tools
  • 新闻
  • 律师
  • 执业领域
  • 法域
  • 新闻和观点
  • 活动
  • 媒体中心
  • 联系方式
  • 职业发展
  • 校友
  • 数据保护和隐私政策
  • 网络隐私和 Cookie 政策
  • 监管
  • 有关费用的监管信息
  • 客户投诉程序
  • 使用条款
  • 反奴役宣言
  • 环境
  • 垃圾电子邮件

© Taylor Wessing